A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase II, 24-week Study Investigating the Efficacy, Safety and Tolerability of AIN457 in Patients With Active Overuse Tendinopathy Refractory to Oral NSAIDs/Acetaminophen, Physiotherapy or Corticosteroid Injections
Phase of Trial: Phase II
Latest Information Update: 15 Nov 2018
At a glance
- Drugs Secukinumab (Primary)
- Indications Musculoskeletal disorders
- Focus Therapeutic Use
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 08 Oct 2018 Planned End Date changed from 9 Aug 2019 to 6 Dec 2019.
- 08 Oct 2018 Planned primary completion date changed from 9 Aug 2019 to 6 Dec 2019.
- 13 Aug 2018 Planned End Date changed from 8 Feb 2019 to 9 Aug 2019.